Nuveen
OTLK icon

Nuveen’s Outlook Therapeutics OTLK Stock Holding History

Nuveen’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-20,079
Closed -$107K – 3338
2024
Q3 		$107K Sell
20,079
-25,802
-56% -$189K ﹤0.01% 3303
2024
Q2 		$339K Buy
+45,881
New +$368K ﹤0.01% 3118
2023
Q3 		– Sell
-29,948
Closed -$1.04M – 3228
2023
Q2 		$1.04M Sell
29,948
-12,835
-30% -$350K ﹤0.01% 2644
2023
Q1 		$933K Buy
42,783
+2,464
+6% +$55.1K ﹤0.01% 2638
2022
Q4 		$871K Sell
40,319
-1,444
-3% -$31.4K ﹤0.01% 2735
2022
Q3 		$1.02M Buy
41,763
+417
+1% +$9.7K ﹤0.01% 2743
2022
Q2 		$843K Sell
41,346
-5,895
-12% -$169K ﹤0.01% 2868
2022
Q1 		$1.92M Buy
47,241
+35,683
+309% +$1.11M ﹤0.01% 2524
2021
Q4 		$308K Sell
11,558
-1,428
-11% -$50.9K ﹤0.01% 3174
2021
Q3 		$625K Buy
12,986
+3,603
+38% +$174K ﹤0.01% 3124
2021
Q2 		$468K Buy
+9,383
New +$435K ﹤0.01% 3168

Other funds holding OTLK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Nuveen's OTLK Position: Q4 2024 in Review

Nuveen sold out of Outlook Therapeutics (OTLK) in Q4 2024, closing a stake of 20,079 shares — an estimated $107K sold.

Nuveen first reported a position in OTLK in Q2 2021 and held it in 11 quarters. The position peaked at $1.92M in Q1 2022. 61 funds tracked by Wall St. Rank hold OTLK as of Q4 2024.

  • Nuveen reported no remaining Outlook Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Nuveen sold 20,079 Outlook Therapeutics shares in Q4 2024, an estimated $107K.
  • Nuveen first reported a position in Outlook Therapeutics in Q2 2021 and held it in 11 quarters.
  • Nuveen's Outlook Therapeutics position peaked at $1.92M in Q1 2022.
  • 61 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q4 2024.

Based on Nuveen's 13F filing for Q4 2024, filed 14 Feb 2025.